Predictors for in-hospital mortality from coronavirus disease 2019 (COVID-19) infection among adults aged 18–65 years

Ashish Bhargava MD, FACP, Mamta Sharma MD, Elisa Akagi MD, Susanna M. Szpunar PhD and Louis Saravolatz MD, MACP, FIDSA
Ascension St John Hospital, Detroit, Michigan

As of October 13, 2020, at least 37,867,739 cases of coronavirus disease 2019 (COVID-19) had been identified worldwide, including ~7,804,699 cases in the United States.1 Early data from the United States showed that 20% of deaths occurred in patients aged 20–64 years and 80% occurred in patients aged ≥65 years.2 Understanding the risk factors associated with mortality among adults aged <65 years may identify vulnerable patients. The purpose of the study was to identify factors present at the time of hospital admission that predicted in-hospital mortality from COVID-19 among adults aged ≤65 years.

Methods
We conducted a retrospective study at a 776-bed, tertiary-care center. The study was approved by the Ascension St John Hospital Institutional Review Board. We included adult patients with confirmed COVID-19 by positive real-time reverse-transcriptase-polymerase chain reaction (RT-PCR) assay of a nasopharyngeal swab for SARS-CoV-2 from March 8 to June 14, 2020. Patient demographics, comorbid conditions, presenting symptoms, initial vital signs, admission laboratory and radiological findings, and outcome variables were extracted from the electronic medical records.

Statistical analyses were performed using SPSS version 27.0 software (IBM, Armonk, NY). Univariable analyses were conducted using the Student t test, the Mann-Whitney U test, and χ2 analysis. Variables that were significant or near-significant predictors of mortality (P < .09) were entered into a multivariable logistic regression model using a forward likelihood ratio algorithm. For comorbidities, the Charlson weighted index of comorbidity (CWIC) score was used instead of individual comorbid conditions.3 Results from the regression are reported as odds ratios with 95% confidence intervals. All reported P values are 2-sided.

Results
In total, 265 hospitalized patients, ages 18–65 years, were included in this study. The mean age of the cohort was 50.4 years (SD, 10.7), 140 (52.8%) were male, and 226 (85.3%) were black/African-American. The mean body mass index of the cohort was 35.8 kg/m2 (SD, 9.3). The mean duration of symptoms prior to hospitalization was 5.8 days (SD, 3.8). Severe pneumonia was diagnosed in 49 patients (18.5%). Mechanical ventilation was required for 66 patients (24.9%). Overall, 214 patients (80.8%) improved clinically and survived to discharge.

The in-hospital case fatality rate (CFR) was 19.2% (51 of 265). Patients who died were significantly older (mean age, 53.4 years vs 49.7 years) than patients who survived (P = .03). Patients who died were significantly more likely to have hypertension, diabetes with chronic complications, hemiplegia, preexisting renal disease, liver disease, and a diagnosis of malignancy (Table 1). The prevalence of lymphocytopenia and thrombocytopenia were higher among patients who died than those who survived.

The Quick Sequential Organ Failure Assessment (qSOFA) score (0–3) is composed of 3 clinical parameters with 1 point allotted to each of these parameters: systolic blood pressure ≤100 mm Hg, respiratory rate ≥22 breaths per minute, and altered mental status. For patients with qSOFA scores of 0, 1, 2, and 3 at the time of hospital admission, the mortality rates were 9.7%, 21.1%, 41.7%, and 60%, respectively (P < .0001).

The final multivariable logistic regression model included 4 variables that predicted increased odds of death in patients with COVID-19 infection: Charlson score, presence of hypertension, qSOFA, and thrombocytopenia at the time of hospital admission (Table 2).

3. Nori P, Cowman K, Chen V, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. Infect Control Hosp Epidemiol. 2020;42:84–88.
4. Giacobbe DR, Battaglini D, Ball L, et al. Bloodstream infections in critically ill patients with COVID-19. Eur J Clin Investig. 2020;50:e13319.
5. Cates J, Lucero-Obusan C, Dahl RM, et al. Risk for in-hospital complications associated with COVID-19 and influenza—Veterans Health Administration, United States, October 1, 2018–May 31, 2020. Morbid Mortal Wkly Rep. 2020.
6. Ripa M, Galli L, Poli A, et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clin Microbiol Infect. 2020;69:1528–1534.
7. Bizzarro MJ, Conrad SA, Kaufman DA, Rycus P. Infections acquired during extracorporeal membrane oxygenation in neonates, children, and adults. Pediatr Crit Care Med. 2011;12:277–281.
8. Shekar K, Badulak J, Peek G, et al. Extracorporeal Life Support Organization coronavirus disease 2019 interim guidelines: a consensus document from an international group of interdisciplinary extracorporeal membrane oxygenation providers. Am Soc Artif Intern Organs J. 2020;66:707–721.
9. Barbaro RP, MacLaren G, Boonstra PS, et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet. 2020;396:1071–1078.

© The Author(s), 2020. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America. This is an Open Access article, distributed under the terms of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Table 1. Univariable Analysis of Predictors for in-Hospital Mortality Among Adults, Aged 18–65 Years From COVID-19 Infection at the Time of Hospital Admission

| Characteristic | Survivors (n=214), No. (%) | Nonsurvivors (n=51), No. (%) | OR (95% CI) | P Value |
|----------------|----------------------------|-------------------------------|-------------|---------|
| **Sex, no. (%)** |                            |                               |             |         |
| Male           | 113 (52.8)                 | 27 (52.9)                     | 1.0 (0.5–1.9) | .98     |
| Female         | 101 (47.2)                 | 24 (47.1)                     |             |         |
| **Race, no. (%)** |                         |                               |             |         |
| White          | 28 (13.1)                  | 5 (9.8)                       | .80         |         |
| Black          | 181 (84.6)                 | 45 (88.2)                     |             |         |
| Other          | 5 (2.3)                    | 1 (2.0)                       |             |         |
| **BMI, mean ± SD** |                     |                               |             |         |
| 35.4 ± 8.8     | 37.7 ± 11.1                |                               | .12         |         |
| **Admission source** |                     |                               |             |         |
| Home           | 184 (86.01)                | 39 (76.5)                     | 1.9 (0.9–4.0) | .10     |
| Nursing facility | 30 (14.0)                | 12 (28.6)                     |             |         |
| **Insurance type** |                     |                               |             |         |
| Commercial     | 108 (50.5)                 | 11 (21.6)                     | 3.7 (1.8–7.6) | <.0001  |
| Public         | 106 (49.5)                 | 40 (78.4)                     |             |         |
| **Comorbidities, no. (%)** |                     |                               |             |         |
| Myocardial infarction | 7 (3.3)                  | 3 (5.9)                       | 1.8 (0.5–7.4) | .38     |
| Congestive heart failure | 20 (9.3)                  | 3 (5.9)                       | 0.6 (0.2–2.1) | .43     |
| Peripheral vascular disease | 10 (4.7)                  | 3 (5.9)                       | 1.3 (0.3–4.8) | .72     |
| Cerebrovascular disease | 21 (9.9)                  | 2 (3.9)                       | 0.4 (0.1–1.6) | .18     |
| Dementia       | 11 (5.1)                   | 4 (7.8)                       | 1.6 (0.5–5.2) | .45     |
| Chronic pulmonary disease | 41 (19.2)                  | 14 (27.5)                     | 1.6 (0.8–3.2) | .19     |
| Connective tissue disease | 2 (0.9)                   | 1 (2.0)                       | 2.1 (0.2–23.8) | .53     |
| Peptic ulcer disease | 7 (3.3)                   | 1 (2.0)                       | 0.6 (0.07–4.9) | .62     |
| Diabetes without chronic complications | 53 (24.8)                  | 11 (17.2)                     | 0.8 (0.4–1.7) | .63     |
| Diabetes with chronic complications | 15 (7.0)                  | 13 (25.5)                     | 4.5 (2.0–10.3) | <.0001  |
| Hemiplegia     | 7 (3.3)                    | 9 (17.6)                      | 6.3 (2.2–18.0) | <.0001  |
| Pre-existing renal disease | 28 (13.1)                  | 13 (25.5)                     | 2.3 (1.1–4.8) | .03     |
| Any malignancy | 2 (0.9)                    | 3 (5.9)                       | 6.6 (1.1–40.7) | .02     |
| Metastatic solid tumor | 0 (0.0)                   | 1 (2.0)                       | ...         | ...     |
| Mild liver disease | 1 (0.5)                    | 2 (3.9)                       | 8.7 (0.8–105.3) | .04     |
| Moderate-severe liver disease | 1 (0.5)                   | 2 (3.9)                       | 8.7 (0.8–97.8) | .04     |
| AIDS           | 3 (1.4)                    | 0 (0.0)                       | ...         | ...     |
| Median CWIC (25th–75th) | 0.0 (0.1)                  | 1.0 (0–3.0)                   | ...         | <.0001  |
| Hypertension   | 129 (60.3)                 | 42 (82.4)                     | 3.1 (1.4–6.6) | .003    |
| Current tobacco smoker | 17 (7.9)                   | 5 (10.0)                      | 1.3 (0.5–3.7) | .67     |
| Obesity        | 149 (71.0)                 | 39 (76.5)                     | 1.3 (0.7–2.7) | .43     |
| History of sick contact | 70 (33.8)                  | 1615 (32.0)                   | 0.9 (0.5–1.8) | .81     |
| **Symptoms, no. (%)** |                     |                               |             |         |
| Fever          | 147 (69.0)                 | 33 (66.0)                     | 0.9 (0.5–1.7) | .68     |
| Shortness of breath | 156 (73.5)                 | 41 (82.0)                     | 1.7 (0.8–3.6) | .20     |
| Cough          | 160 (75.5)                 | 34 (69.4)                     | 0.7 (0.4–1.5) | .38     |
| Loss of taste  | 35 (16.7)                  | 5 (10.4)                      | 0.6 (0.2–1.6) | .28     |
| **Vitals on admission** |                     |                               |             |         |
| Systolic BP, mean ± SD | 135.6 ± 23.7              | 136.0 ± 29.3                  | 0.92        |         |
| Diastolic BP, mean ± SD | 76.7 ± 15.9              | 76.2 ± 1729                   | .85         |         |

(Continued)
In our study, the CFR among patients aged ≤65 years was 19.2%, which is similar to previous US studies, in which mortality ranged from 8.3% to 22.7%. The qSOFA score was introduced by the Sepsis-3 task force as a tool to assist in the early identification of patients at risk of sepsis. Patients with a qSOFA score of 2 or higher had a mortality rate of 24% compared to 3% among patients with a qSOFA score of <2. In our study, a qSOFA score of 2 was associated with a mortality rate of 41.7%.

Thrombocytopenia in critically ill patients usually suggests serious organ malfunction or physiologic decompensation, often evolving toward disseminated intravascular coagulation. In a meta-analysis, a lower platelet count was encountered in nonsurviving COVID-19 patients. In our study, 37.3% of nonsurvivors had thrombocytopenia on presentation compared to 13.6% of survivors.

Similar to clinical studies, we found that a higher Charlson score was an independent predictor of mortality. In terms of individual comorbidities, hypertension, diabetes with chronic complications, hemiplegia, renal disease, malignancy, and liver disease, were associated with mortality. Previous studies from China have reported mortality in patients with comorbidities of 10.5% for cardiovascular disease, 7.3% for diabetes, 6.3% for chronic respiratory disease, 6% for hypertension, and 5.6% for cancer. Previously, we reported that acute or pre-existing renal disease was an independent predictor for severe COVID-19 infection.

A study of adults aged 18–34 years identified significantly higher mortality among patients with hypertension.

This study has several limitations. It was limited by the sample size. This study was a single institution study of admitted patients.

Table 1. (Continued)

| Characteristic                          | Survivors (n=214), No. (%) | Nonsurvivors (n=51), No. (%) | OR (95% CI) | P Value |
|----------------------------------------|----------------------------|------------------------------|-------------|---------|
| Heart rate, mean ± SD                  | 104.1 ± 21.2               | 112.7 ± 21.0                 | .02         |         |
| Respiratory rate, mean ± SD            | 22.8 ± 7.0                 | 27.1 ± 8.4                   | <.0001      |         |
| Fever, no. (%)                         | 88 (41.1)                  | 21 (41.2)                    | 1.0 (0.5–1.9) | .99     |
| Oxygen saturation, mean ± SD           | 0.94 ± 0.06                | 0.91 ± 0.09                  | .001        |         |
| qSOFA scores                           |                            |                              | <.0001      |         |
| 0                                      | 93 (43.5)                  | 10 (19.6)                    | .76         |         |
| 1                                      | 105 (49.1)                 | 28 (54.9)                    | .04         |         |
| 2                                      | 14 (6.5)                   | 10 (19.6)                    | .29         |         |
| 3                                      | 2 (0.9)                    | 3 (5.9)                      | .10         |         |
| Abnormal chest x-ray on admission, no. (%) | 152 (71.0)               | 42 (82.4)                    | 1.9 (0.9–4.1) | .22     |
| Laboratory findings on admission, no. (%) |                        |                              |             |         |
| Leukopenia                             | 22 (10.3)                  | 6 (11.8)                     | 1.2 (0.5–3.0) | .76     |
| Lymphocytopenia (<1.0×10⁹/L)           | 84 (39.3)                  | 28 (54.9)                    | 1.9 (1.0–3.5) | .04     |
| Thrombocytopenia (<150×10⁹/L)          | 29 (13.6)                  | 19 (37.3)                    | 3.8 (1.9–7.5) | <.0001  |
| Elevated AST (>40 U/L)                 | 110 (53.9)                 | 33 (71.7)                    | 2.2 (1.1–4.4) | .03     |
| Elevated ALT (>40 U/L)                 | 81 (38.8)                  | 15 (30.6)                    | 0.7 (0.4–1.4) | .29     |
| Low serum protein (<6.2 gm/dL)         | 6 (2.9)                    | 5 (10.2)                     | 3.8 (1.1–13.1) | .02     |
| Low serum albumin (<3.5 gm/dL)         | 60 (28.8)                  | 26 (53.1)                    | 2.8 (1.5–5.3) | .001    |
| Elevated creatinine (from baseline)    | 55 (26.6)                  | 27 (57.4)                    | 3.7 (1.9–7.2) | <.0001  |
| Positive blood culture on admission    | 5 (5.2)                    | 3 (12.0)                     | 2.5 (0.6–11.2) | .22     |
| Clinical diagnosis, no. (%)            |                            |                              |             |         |
| Uncomplicated illness                  | 103 (48.1)                 | 17 (33.3)                    | .008        |         |
| Mild pneumonia                         | 79 (36.9)                  | 17 (33.3)                    |             |         |
| Severe pneumonia                       | 32 (15.0)                  | 17 (33.3)                    |             |         |

Note: OR, odds ratio; CI, confidence interval; BMI, body mass index; SD, standard deviation; AIDS, acquired immunodeficiency syndrome; CWIC, Charlson weighted index of comorbidity; BP, blood pressure; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CRP, C-reactive protein; qSOFA, quick sepsis-related organ-failure assessment.

Table 2. Multivariable Analysis of Predictors for In-Hospital Mortality Among Adults, Aged 18–65 Years From COVID-19 Infection at the Time of Hospital Admission

| Variables                          | OR (95% CI) | P Value |
|------------------------------------|-------------|---------|
| CWIC score                         | 1.3 (1.1–1.6) | <.0001  |
| Thrombocytopenia                   | 3.5 (1.5–8.0) | .003    |
| Hypertension                       | 2.8 (1.1–6.8) | .03     |
| qSOFA score of 1<sup>a</sup>       | 3.1 (1.3–7.8) | .02     |
| qSOFA score of 2<sup>a</sup>       | 6.2 (1.8–20.9) | .003    |
| qSOFA score of 3<sup>a</sup>       | 15.2 (1.7–135.2) | .02    |

Note: OR, odds ratio; CI, confidence interval; CWIC, Charlson weighted index of comorbidity; qSOFA, quick sepsis-related organ-failure assessment. qSOFA 1 has a score of 1, qSOFA 2 has a score of 2, and qSOFA 3 has a score of 3.<br><sup>a</sup>Compared to a qSOFA score of zero.

Discussion

In our study, the CFR among patients aged ≤65 years was 19.2%, which is similar to previous US studies, in which mortality ranged from 8.3% to 22.7%. The qSOFA score was introduced by the Sepsis-3 task force as a tool to assist in the early identification...
which makes generalization difficult. Because of the retrospective design, certain laboratory results were sometimes unavailable on admission, including lactate dehydrogenase, D-dimer, and serum ferritin. Patients with chronic lung disease and conditions associated with immunosuppression were only a small percentage among hospitalized patients. Therefore, the role of some of these variables in predicting mortality from COVID-19 could have been underestimated.

In conclusion, calculation of the qSOFA score bedside at the time of admission can predict mortality among COVID-19 patients aged ≤65 years. These findings can be applied globally, including resource-limited countries. Subsequent research involving multiple study sites and with a larger database can further validate the findings of our study.

Acknowledgments.

Financial support. This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of interest. All authors have no association that might pose a conflict of interest.

References

1. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Johns Hopkins University website. https://coronavirus.jhu.edu/map.html. Published 2020. Accessed October 13, 2020.

Coronavirus disease 2019 vaccine hesitancy among children’s hospital staff: A single-center survey

Larry K. Kociolek MD, MSCI1,2, Jenny Elhadary PharmD1, Ravi Jhaveri MD1,2, Ami B. Patel MD, MPH1,2, Brian Stahulak DNP, MBA1 and Jenifer Cartland PhD1,2

1Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois and 2Northwestern University Feinberg School of Medicine, Chicago, Illinois

The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine was authorized for emergency use on December 11, 2020,1 after demonstrating excellent efficacy and safety in a large phase 3 clinical trial in adults and adolescents.2 The Advisory Committee on Immunization Practices through the Centers for Disease Control and Prevention then recommended its use,3 prompting delivery to US hospitals for healthcare worker vaccination. To help guide our children’s hospital workforce vaccine advocacy efforts, we designed a survey assessing frequency of vaccine hesitancy, characteristics of those reporting vaccine hesitancy, specific concerns, and communication preferences.

Methods

This survey was performed at the Ann & Robert H. Lurie Children’s Hospital of Chicago, a 360-bed academic free-standing children’s hospital with multiple satellite outpatient and surgical centers. On December 21, 2020, the first day of administration of the Pfizer-BioNTech COVID-19 vaccine to our workforce, a 17-question electronic survey (Supplemental Material online) was sent to all individuals with an active Lurie Children’s email address. This survey included all clinical (eg, attending physicians, housekeeping staff, advanced practice staff, and ancillary healthcare workers), and non-clinical (eg, administrative, support, and research) staff. After 3 e-mail reminders were sent, the survey was closed on January 13, 2021. The survey was anonymous, and all questions were optional. During the 2 weeks before the survey, vaccine information was communicated to staff through a virtual town hall, and answers to frequently asked questions were emailed to all staff. Statistical analyses were performed using Stata/IC version 16.0 software (StataCorp, College Station, TX). Descriptive statistics were measured, prevalence ratios were